Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 4
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
4| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8445515 | TAVNEOSavacopan | substance, product | Feb 2031 |
| 8906938 | TAVNEOSavacopan | substance, product | Jan 2034 |
| 11603356 | TAVNEOSavacopan | substance, product | Nov 2039 |
| 11951214 | TAVNEOSavacopan | product | Nov 2039 |
| Product | Exclusivity | Until |
|---|---|---|
| TAVNEOSAVACOPAN | ODE-377 Orphan drug | Oct 2028 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| TAVNEOS | avacopan | capsule, oral | 73556-168NDA |
Enquiry
Common questions
- Is ChemoCentryx, Inc. FDA approved?
- ChemoCentryx, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does ChemoCentryx, Inc. make?
- 1 product is listed under ChemoCentryx, Inc. in the openFDA NDC Directory, most often as capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.